{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:03:41Z","timestamp":1767175421841,"version":"build-2238731810"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive bile duct destruction, leading to cholestasis and, if untreated, liver failure. Although ursodeoxycholic acid (UDCA) remains the first-line treatment, many patients exhibit an inadequate response, necessitating alternative therapeutic options. Seladelpar, a peroxisome proliferator-activated receptor delta (PPAR-\u03b4) agonist, has emerged as a promising alternative due to its anti-inflammatory and anti-fibrotic properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted to evaluate the efficacy and safety of Seladelpar in patients with PBC. A comprehensive database search was performed to identify studies comparing Seladelpar with placebo. Primary and secondary outcomes, including alkaline phosphatase (ALP) normalization, biochemical response, and adverse events, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three RCTs, comprising 496 patients, were included. Seladelpar significantly improved ALP normalization and biochemical response compared to placebo. Additionally, it effectively reduced ALP and ALT levels from baseline to follow-up. Adverse events, including abdominal pain and headache, were reported, with a higher incidence observed in the Seladelpar group, while other adverse events showed no significant differences between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Seladelpar appears to be an effective treatment for PBC, demonstrating significant improvements in key liver function markers. While it has shown therapeutic benefits, further research is warranted to evaluate its long-term safety, particularly regarding adverse event incidence, and to determine its efficacy across different dosages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-03812-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T02:51:12Z","timestamp":1743821472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Taimoor","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abunada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandlal","family":"Seerani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kashif","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areej","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Lamiya","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Adil Mir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Hassaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asfia","family":"Qammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. N. U.","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih Abdella","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"3812_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-3-030-24432-3_24","volume":"3","author":"EI Rigopoulou","year":"2020","unstructured":"Rigopoulou EI. Primary biliary cholangitis. Liver Dis. 2020;3:247\u201359.","journal-title":"Liver Dis"},{"key":"3812_CR2","doi-asserted-by":"crossref","unstructured":"Abbas SN, Jones D, Kallis Y, Maher L, Patanwala I. Primary biliary cholangitis: assessment and management strategies. Gastrointestinal Nursing. 2021;19(Sup4):S1\u201324. Available from: https:\/\/www.magonlinelibrary.com\/doi\/10.12968\/gasn.2021.19.Sup4.S1.","DOI":"10.12968\/gasn.2021.19.Sup4.S1"},{"issue":"1","key":"3812_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.56367\/OAG-039-10859","volume":"39","author":"CS Umeshappa","year":"2023","unstructured":"Umeshappa CS. Understanding immune mechanisms to create novel treatments for primary biliary cholangitis. Open Access Govern. 2023;39(1):116\u20137.","journal-title":"Open Access Govern"},{"key":"3812_CR4","doi-asserted-by":"crossref","unstructured":"Abboud Y, Chaar A, \u2026 TAO journal of the, 2023 undefined. S1359 trends of primary biliary cholangitis among hospitalized patients in the United States Between 2011-2020: a nationwide cohort analysis. journals.lww.comY Abboud, AK Chaar, T Aboursheid, A Khrais, A Mittal, NT PyrsopoulosOfficial journal of the American College of Gastroenterology| ACG, 2023\u2022journals.lww.com. Available from: https:\/\/journals.lww.com\/ajg\/fulltext\/2023\/10001\/s1359_trends_of_primary_biliary_cholangitis_among.2320.aspx. Cited 2024 Mar 10.","DOI":"10.14309\/01.ajg.0000955076.23136.66"},{"key":"3812_CR5","doi-asserted-by":"publisher","unstructured":"Corpechot C, Poupon R, Chazouill\u00e8res O. New treatments\/targets for primary biliary cholangitis. JHEP Rep. 2019;1(3):203\u201313. https:\/\/doi.org\/10.1016\/j.jhepr.2019.05.005. PMID: 32039371; PMCID: PMC7001536.","DOI":"10.1016\/j.jhepr.2019.05.005"},{"key":"3812_CR6","unstructured":"Jones D, Boudes P, Swain M, \u2026 CBT lancet, 2017 undefined. Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind. thelancet.comD Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, Y Doerffel, N GitlinThe lancet Gastroenterology & hepatology, 2017\u2022thelancet.com. 2017;2(10):716\u201326. Available from: https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(17)30246-7\/fulltext. Cited 2024 Mar 10."},{"key":"3812_CR7","doi-asserted-by":"publisher","unstructured":"Zhang F, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-\u03b3 cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal. 2012;24(3):596-605. https:\/\/doi.org\/10.1016\/j.cellsig.2011.11.008. Epub 2011 Nov 13. PMID: 22108088.","DOI":"10.1016\/j.cellsig.2011.11.008"},{"key":"3812_CR8","doi-asserted-by":"crossref","unstructured":"Wetten A, Jones D, Investigational JDEO on, 2022 undefined. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). Taylor & FrancisA Wetten, DEJ Jones, JK DysonExpert Opinion on Investigational Drugs, 2022\u2022Taylor & Francis. 2022; Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2130750. Cited 2024 Mar 10.","DOI":"10.1080\/13543784.2022.2130750"},{"key":"3812_CR9","doi-asserted-by":"crossref","unstructured":"Kremer AE, Mayo MJ, Hirschfield G, Levy C, Bowlus CL, Jones DE, et al. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Wiley Online LibraryAE Kremer, MJ Mayo, G Hirschfield, C Levy, CL Bowlus, DE Jones, A SteinbergLiver international, 2022\u2022Wiley Online Library. 2021;42(1):112\u201323. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/liv.15039. Cited 2024 Mar 10.","DOI":"10.1111\/liv.15039"},{"key":"3812_CR10","doi-asserted-by":"publisher","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladr\u00f3n de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londo\u00f1o Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024;390(9):783-794.  https:\/\/doi.org\/10.1056\/NEJMoa2312100. Epub 2024 Feb 21. PMID: 38381664.","DOI":"10.1056\/NEJMoa2312100"},{"key":"3812_CR11","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj.com. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71.short. Cited 2024 Mar 10."},{"issue":"2","key":"3812_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","volume":"78","author":"GM Hirschfield","year":"2023","unstructured":"Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78(2):397\u2013415. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37386786\/. Cited 2024 Mar 10.","journal-title":"Hepatology"},{"issue":"9","key":"3812_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38381664\/. Cited 2024 Mar 10.","journal-title":"N Engl J Med"},{"key":"3812_CR14","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31462531\/. Cited 2024 Jun 30.","DOI":"10.1136\/bmj.l4898"},{"key":"3812_CR15","doi-asserted-by":"crossref","unstructured":"Higgins J, Thompson S, Deeks J, Bmj DA, 2003 undefined. Measuring inconsistency in meta-analyses. bmj.com. Available from: https:\/\/www.bmj.com\/content\/327\/7414\/557.short. Cited 2024 Feb 27.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"3812_CR16","doi-asserted-by":"crossref","unstructured":"Ghonem N, Assis D, Hepatology JB, 2015 undefined. Fibrates and cholestasis. Wiley Online LibraryNS Ghonem, DN Assis, JL BoyerHepatology, 2015\u2022Wiley Online Library. 2015;62(2):635\u201343. Available from: https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.27744. Cited 2024 Mar 10.","DOI":"10.1002\/hep.27744"},{"key":"3812_CR17","first-page":"6","volume":"1","author":"F Colapietro","year":"2023","unstructured":"Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun. 2023;1:6.","journal-title":"J Transl Autoimmun"},{"issue":"18","key":"3812_CR18","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1021\/jm049904b","volume":"47","author":"R Pellicciari","year":"2004","unstructured":"Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure - Activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47(18):4559\u201369.","journal-title":"J Med Chem"},{"key":"3812_CR19","doi-asserted-by":"crossref","unstructured":"Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor \u03baB in hepatic inflammatory response. journals.lww.com. 2008;48(5):1632\u201343. Available from: https:\/\/journals.lww.com\/hep\/fulltext\/2008\/11000\/Farnesoid_X_receptor_antagonizes_nuclear_factor__B.32.aspx. Cited 2024 Mar 10.","DOI":"10.1002\/hep.22519"},{"issue":"4","key":"3812_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14656566.2014.876992","volume":"15","author":"A Sahebkar","year":"2014","unstructured":"Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-Activated receptor agonists: potential treatments for atherogenic Dyslipidemia and non-Alcoholic fatty liver disease. Expert Opin Pharmacother. 2014;15(4):493\u2013503.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"3812_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hep4.1072","volume":"1","author":"F Haczeyni","year":"2017","unstructured":"Haczeyni F, Wang H, Barn V, Mridha AR, Yeh MM, Haigh WG, et al. The selective peroxisome proliferator\u2013activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017;1(7):663\u201374.","journal-title":"Hepatol Commun"},{"key":"3812_CR22","doi-asserted-by":"crossref","unstructured":"Kouno T, Liu X, Zhao H, Kisseleva T, et al., 2022 undefined. Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. ASBMB. 2022. Available from: https:\/\/www.jbc.org\/article\/S0021-9258(22)00496-3\/abstract. Cited 2024 Mar 10.","DOI":"10.1016\/j.jbc.2022.102056"},{"key":"3812_CR23","doi-asserted-by":"crossref","unstructured":"Lin W, Wang J, Reviews YLS, 2024 undefined. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network. SpringerW Lin, J Wang, Y LiuSystematic Reviews, 2024\u2022Springer. 2024;13(1). Available from: https:\/\/link.springer.com\/article\/10.1186\/s13643-024-02460-0. Cited 2024 Mar 10.","DOI":"10.1186\/s13643-024-02460-0"},{"key":"3812_CR24","doi-asserted-by":"publisher","unstructured":"Dubois V, Eeckhoute J, Lefebvre P, Staels B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest. 2017;127(4):1202\u201314. https:\/\/doi.org\/10.1172\/JCI88894. Epub 2017 Apr 3. PMID: 28368286; PMCID: PMC5373878.","DOI":"10.1172\/JCI88894"},{"key":"3812_CR25","doi-asserted-by":"crossref","unstructured":"Mayo MJ, Vierling JM, Bowlus CL, Hirschfield GM, Borg BB, Harrison SA, et al. Open\u2010label, clinical trial extension: two\u2010year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Wiley Online LibraryMJ Mayo, JM Vierling, CL Bowlus, C Levy, GM Hirschfield, GW Neff, MR GalambosAlimentary Pharmacology & Therapeutics, 2024\u2022Wiley Online Library. 2023;59(2):186\u2013200. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/apt.17755. Cited 2024 Mar 10.","DOI":"10.1111\/apt.17755"},{"key":"3812_CR26","unstructured":"Seladelpar reduces cholestasis, liver injury and improves pruritus in phase 3. Available from: https:\/\/www.rarediseaseadvisor.com\/reports\/seladelpar-reduces-cholestasis-liver-injury-improves-pruritus-phase-3-trial\/. Cited 2024 Mar 10."},{"issue":"2","key":"3812_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","volume":"77","author":"CL Bowlus","year":"2022","unstructured":"Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, D\u00f6rffel Y, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022;77(2):353\u201364.","journal-title":"J Hepatol"},{"issue":"6","key":"3812_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2174\/1381612822666161006151134","volume":"23","author":"D Nikolic","year":"2017","unstructured":"Nikolic D, Castellino G, Banach M, Toth P, Ivanova E, Orekhov A, et al. PPAR agonists, atherogenic dyslipidemia and cardiovascular risk. Curr Pharm Des. 2017;23(6):894\u2013902. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27719644\/. Cited 2025 Mar 10.","journal-title":"Curr Pharm Des"},{"key":"3812_CR29","doi-asserted-by":"crossref","unstructured":"Wagner N, Wagner KD. Pharmacological utility of PPAR modulation for angiogenesis in cardiovascular disease. Int J Mol Sci. 2023;24(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36768666\/. Cited 2025 Mar 10.","DOI":"10.3390\/ijms24032345"},{"issue":"12","key":"3812_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809\u201323. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34127848\/. Cited 2025 Mar 10.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"3812_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJMe2312745","volume":"390","author":"DN Assis","year":"2024","unstructured":"Assis DN. Advancing second-line treatment for primary biliary cholangitis. N Engl J Med. 2024;390(9):853\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38381658\/. Cited 2024 Jun 20.","journal-title":"N Engl J Med"},{"key":"3812_CR32","unstructured":"CymaBay\u2019s seladelpar achieves high statistical significance for the primary and key secondary endpoints in the phase 3 RESPONSE trial in primary biliary cholangitis\u202f:: CymaBay Therapeutics (CBAY). Available from: https:\/\/www.cymabay.com\/investors-media\/news-events\/press-releases\/detail\/569\/cymabays-seladelpar-achieves-high-statistical-significance. Cited 2024 Jun 20."}],"updated-by":[{"DOI":"10.1186\/s12876-025-04214-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000}}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03812-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:12:32Z","timestamp":1757157152000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03812-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12876-025-04214-1","URL":"https:\/\/doi.org\/10.1186\/s12876-025-04214-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}